In vitro cytotoxicity against Marek's disease lymphoblastoid cell lines after enzymatic removal of Marek's disease tumor-associated surface antigen.
AUTOR(ES)
Schat, K A
RESUMO
Marek's disease tumor-associated surface antigen (MATSA) has been claimed to be the target of cytotoxic lymphocytes in in vitro tests for Marek's disease immunity. Treatment with papain, but not with trypsin or mixed glycosidases, removed MATSA from certain Marek's disease lymphoblastoid cell lines. Tumor cells with and without MATSA were used as target cells for in vitro studies on cell-mediated immune responses with sensitized spleen cells in a chromium release assay. The removal of MATSA did not influence the results of the chromium release assay. Attempts to block the cell-mediated cytotoxicity in vitro by coating tumor cells with an anti-MATSA serum failed. It was concluded that cell-mediated immune responses against Marek's disease tumor cells are directed against an as yet undefined antigen(s).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=288678Documentos Relacionados
- Development and characterization of monoclonal antibodies to Marek's disease tumor-associated surface antigen.
- Pathogenesis of Marek's disease; effect of immunization with inactivated viral and tumor-associated antigens.
- Nature of the tumor-associated determinant(s) of carcinoembryonic antigen.
- In vitro establishment of Marek's disease herpesvirus-transformed productive and nonproductive lymphoblastoid cell lines.
- Marek's disease herpesviruses. IV. Molecular characterization of Marek's disease herpesvirus A antigen.
